Q-omics provides the consensus-scored RPL6P24 profile across patient tissues and cancer cell-line models. RPL6P24 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL6P24 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RPL6P24 RNA expression shows 7,208 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, THCA, and HNSC as cancer lineages where RPL6P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P24 survival associations across molecular data types. RPL6P24 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P24 RNA expression–survival associations across cancer types. High RPL6P24 expression shows unfavorable associations in KIRP, LIHC, ACC and LUSC, but favorable associations in HNSC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL6P24 RNA expression.
This table summarizes RPL6P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P24 shows lower tumor expression in THCA, PAAD and LUAD and higher tumor expression in CHOL, LIHC and PRAD. The THCA box plot shows higher RPL6P24 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .031).
This table shows molecular features associated with RPL6P24 in patient tissues and cancer cell lines. In patient samples, RPL6P24 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
